Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...
New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback